Phase II study of ARN-6039 in multiple sclerosis patients.

Trial Profile

Phase II study of ARN-6039 in multiple sclerosis patients.

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs ARN 6039 (Primary)
  • Indications Multiple sclerosis
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 09 Jun 2016 New trial record
    • 03 Jun 2016 According to Arrien Pharmaceuticals media release, the company hopes to move the Phase I program through this Phase II trial towards the end of the year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top